Άκης
Administrator
Σύντομα (??), αναμένεται να κυκλοφορήσει και ένα νέο προϊόν. Το όνομα του, μέχρι στιγμής πιστεύω, είναι ASC-J9 Foam.Όπως καταλάβατε από το όνομα, θα είναι τοπικός αφρός και όχι κάποιο χάπι.
Αν και αναφέρεται καιρό, αυτό το καιρό αναμένεται να περάσει τα τεστ φάσης 2 του FDA.
Ναι, πάει για FDA.
"AndroScience Corporation is expected to start a Phase 2 clinical study in men with
AGA, using topical ASC-J9 Foam, in Q4 of 2008."
Για τι πρόκειται; “novel anti-androgen that enhances androgen receptor degradation.”
Από το site τους
"AndroScience recently discovered and patented their family of compounds which are derived from natural products. They claim these compounds selectively enhance androgen receptor degradation and do not affect endogenous androgens, testosterone or dihydrotestosterone (DHT).
This is a very interesting and exciting potential treatment for Androgenetic Alopecia.
Conventional hair loss treatments like Propecia work by reducing the bodies’ production of DHT, the hormone that causes male pattern baldness (MPB). The problem is that a reduction of DHT in the body can lead to unwanted side effects.
One way around this is to attack the problem in a different way and to block the androgen receptor sites where the DHT attaches to the cells, thus preventing the DHT from harming the hair follicle.
What this new compound appears to do is to go one step further and actually damage or degrade the androgen receptors. Since it’s a topical product it should allow a hair follicle to essentially become immune to the effects of DHT while not causing any other side effects in the body.
If this does work as intended it could be a huge breakthrough in hair loss treatments.
AndroScience won the Third Place Award (out of >900 posters) for its presentation entitled “Androgen Receptor Degradation (ARD) Enhancer: A Potential Application for Topical Treatment of Acne Vulgaris” at the Annual Meeting of American Academy of Dermatology in March of 2006; and in July 2006, AndroScience was awarded a Phase II SBIR grant ($800,000) from the NIH to develop ASC-J9 for acne treatment."
Αν και αναφέρεται καιρό, αυτό το καιρό αναμένεται να περάσει τα τεστ φάσης 2 του FDA.
Ναι, πάει για FDA.
"AndroScience Corporation is expected to start a Phase 2 clinical study in men with
AGA, using topical ASC-J9 Foam, in Q4 of 2008."
Για τι πρόκειται; “novel anti-androgen that enhances androgen receptor degradation.”
Από το site τους
"AndroScience recently discovered and patented their family of compounds which are derived from natural products. They claim these compounds selectively enhance androgen receptor degradation and do not affect endogenous androgens, testosterone or dihydrotestosterone (DHT).
This is a very interesting and exciting potential treatment for Androgenetic Alopecia.
Conventional hair loss treatments like Propecia work by reducing the bodies’ production of DHT, the hormone that causes male pattern baldness (MPB). The problem is that a reduction of DHT in the body can lead to unwanted side effects.
One way around this is to attack the problem in a different way and to block the androgen receptor sites where the DHT attaches to the cells, thus preventing the DHT from harming the hair follicle.
What this new compound appears to do is to go one step further and actually damage or degrade the androgen receptors. Since it’s a topical product it should allow a hair follicle to essentially become immune to the effects of DHT while not causing any other side effects in the body.
If this does work as intended it could be a huge breakthrough in hair loss treatments.
AndroScience won the Third Place Award (out of >900 posters) for its presentation entitled “Androgen Receptor Degradation (ARD) Enhancer: A Potential Application for Topical Treatment of Acne Vulgaris” at the Annual Meeting of American Academy of Dermatology in March of 2006; and in July 2006, AndroScience was awarded a Phase II SBIR grant ($800,000) from the NIH to develop ASC-J9 for acne treatment."
)
